Early Access

10-QPeriod: Q1 FY2025

AMETEK INC/ Quarterly Report for Q1 Ended Mar 31, 2025

Filed May 1, 2025For Securities:AME

Summary

AMETEK, Inc. (AME) reported its first-quarter 2025 financial results, demonstrating resilience in a dynamic market. While net sales saw a slight year-over-year decrease of 0.2% to $1,732.0 million, this was largely due to a 1% organic sales decline, offset by a 1% contribution from recent acquisitions. The company reported strong orders growth of 8.1% to $1,797.8 million, indicating robust future demand, and its backlog increased to $3,469.1 million. Net income rose by a significant 13.1% to $351.8 million, translating to diluted earnings per share (EPS) of $1.52, up from $1.34 in the prior year. This performance highlights the company's effective cost management and operational efficiency initiatives, which are driving improved profitability and margins.

Financial Statements
Beta

Key Highlights

  • 1Net sales for Q1 2025 were $1,732.0 million, a marginal decrease of 0.2% compared to Q1 2024, reflecting a slight organic sales decline offset by acquisition contributions.
  • 2Strong order growth of 8.1% to $1,797.8 million in Q1 2025 signals positive future revenue potential, with backlog increasing to $3,469.1 million.
  • 3Net income increased by 13.1% to $351.8 million, and diluted EPS grew by 13.4% to $1.52, demonstrating improved profitability.
  • 4Operating income rose by 9.0% to $454.8 million, with operating margins expanding to 26.3% from 24.0% in the prior year, driven by operational excellence initiatives and reduced integration costs.
  • 5The company successfully integrated two acquisitions, Virtek Vision International and Kern Microtechnik, contributing 1% to net sales growth.
  • 6Free cash flow generation remained strong, totaling $394.5 million for the quarter, an increase from $382.6 million in the prior year, supporting financial flexibility.
  • 7AMETEK increased its quarterly cash dividend by 11% to $0.31 per common share, reflecting confidence in its financial health and commitment to shareholder returns.

Frequently Asked Questions